JP2011522864A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522864A5 JP2011522864A5 JP2011512988A JP2011512988A JP2011522864A5 JP 2011522864 A5 JP2011522864 A5 JP 2011522864A5 JP 2011512988 A JP2011512988 A JP 2011512988A JP 2011512988 A JP2011512988 A JP 2011512988A JP 2011522864 A5 JP2011522864 A5 JP 2011522864A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- seq
- medicament
- amino acid
- cac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010056340 Diabetic ulcer Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000000558 Varicose Ulcer Diseases 0.000 claims 1
- 208000032594 Vascular Remodeling Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6116308P | 2008-06-13 | 2008-06-13 | |
| US61/061,163 | 2008-06-13 | ||
| PCT/EP2009/057263 WO2009150214A2 (en) | 2008-06-13 | 2009-06-12 | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011522864A JP2011522864A (ja) | 2011-08-04 |
| JP2011522864A5 true JP2011522864A5 (cg-RX-API-DMAC7.html) | 2012-07-05 |
| JP5481473B2 JP5481473B2 (ja) | 2014-04-23 |
Family
ID=41078180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011512988A Expired - Fee Related JP5481473B2 (ja) | 2008-06-13 | 2009-06-12 | 糖尿病患者における血管リモデリングおよび心血管疾患治療のための治療薬としての非アシル化グレリンおよび類似体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8476408B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2310041B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5481473B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102065883A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009256558B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2723270C (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010013677A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009150214A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9651708B2 (en) * | 2011-04-21 | 2017-05-16 | Baker Hughes Incorporated | Method of mapping reservoir fluid movement using gravity sensors |
| PT2790721T (pt) * | 2011-12-15 | 2019-01-24 | Millendo Therapeutics Sas | Fragmentos de grelina não acilada para usar no tratamento da síndrome de prader-willi |
| US10016458B2 (en) | 2012-04-16 | 2018-07-10 | Baystate Health, Inc. | p53 silenced endothelial progenitor cells for diabetes |
| WO2013190520A2 (en) | 2012-06-22 | 2013-12-27 | The General Hospital Corporation | Gh-releasing agents in the treatment of vascular stenosis and associated conditions |
| WO2014203074A2 (en) | 2013-06-21 | 2014-12-24 | Alize Pharma Sas | Use of unacylated ghrelin, fragments and analogs thereof as antioxidant |
| EP3137098A4 (en) * | 2014-04-29 | 2017-11-01 | Mayo Foundation for Medical Education and Research | Butyrylcholinesterases having an enhanced ability to hydrolyze acyl ghrelin |
| WO2018053216A1 (en) | 2016-09-15 | 2018-03-22 | Mayo Foundation For Medical Education And Research | Methods and materials for using butyrylcholinesterases to treat cancer |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643872A (en) * | 1989-10-23 | 1997-07-01 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| US5747296A (en) * | 1992-05-11 | 1998-05-05 | Corvas International, Inc. | Method of detecting neutophil inhibitory factor mimics |
| WO1994013692A1 (en) * | 1992-12-10 | 1994-06-23 | Regents Of The University Of Minnesota | Polypeptides useful for treating inflammatory disorders |
| US5786332A (en) * | 1995-03-06 | 1998-07-28 | Trega Biosciences, Inc. | Cytokine restraining agents and methods of use in pathologies and conditions associated with altered cytokine levels |
| WO1995014787A1 (en) * | 1993-11-22 | 1995-06-01 | Centocor, Inc. | Peptide inhibitors of selecting binding |
| US5695761A (en) * | 1993-12-23 | 1997-12-09 | Rutgers University | Suppression of nitric oxide production by osteopontin |
| KR100360639B1 (ko) * | 1994-03-09 | 2003-01-30 | 코르텍, 인크. | N-치환글리신함유브라디키닌길항제펩티드 |
| US5958875A (en) * | 1996-03-29 | 1999-09-28 | The Regents Of The University Of California | Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity |
| US6627729B1 (en) | 1997-03-24 | 2003-09-30 | Zymogenetics, Inc. | TML peptides |
| US5932548A (en) * | 1998-06-03 | 1999-08-03 | Deghenghi; Romano | Lysine containing peptides for treatment of heart disease |
| WO2000023469A2 (en) * | 1998-10-16 | 2000-04-27 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
| WO2001056592A1 (en) | 2000-02-01 | 2001-08-09 | Novo Nordisk A/S | Use of compounds for the regulation of food intake |
| WO2001087335A2 (en) | 2000-05-17 | 2001-11-22 | Eli Lilly And Company | Method for selectively inhibiting ghrelin action |
| CA2411667A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co. Inc. | Ghrelin analogs |
| JP4493913B2 (ja) | 2001-01-31 | 2010-06-30 | 中外製薬株式会社 | 低栄養症状疾患治療剤 |
| US6872548B2 (en) | 2001-01-31 | 2005-03-29 | Human Genome Sciences, Inc. | Scaffolded fusion polypeptides and compositions and methods for making the same |
| CA2470235C (en) | 2001-12-18 | 2012-02-07 | Theratechnologies Inc. | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| US7666833B2 (en) | 2001-12-18 | 2010-02-23 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| WO2003051389A2 (en) | 2001-12-18 | 2003-06-26 | Theratechnologies Inc. | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| CN100411683C (zh) | 2002-05-21 | 2008-08-20 | 阿斯比奥制药株式会社 | 含有生长素释放肽的药物组合物 |
| US20050002897A1 (en) * | 2003-06-18 | 2005-01-06 | Ulrich Haupts | Biological entities and the pharmaceutical or diagnostic use thereof |
| US7517269B2 (en) | 2003-08-12 | 2009-04-14 | Parvia Corp. | Building element for constructing a modular substructure |
| US7825090B2 (en) | 2003-10-24 | 2010-11-02 | Alizé Pharma SAS | Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance |
| US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| WO2006019577A1 (en) * | 2004-07-14 | 2006-02-23 | Eli Lilly And Company | Anti-ghrelin antibodies |
| WO2006045319A2 (en) | 2004-10-27 | 2006-05-04 | Gastrotech Pharma A/S | Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure |
| JP2008520204A (ja) * | 2004-11-15 | 2008-06-19 | イーライ リリー アンド カンパニー | 非アシル化グレリン抗体及びその治療への使用 |
| EP2021365B1 (en) | 2006-03-28 | 2012-05-30 | Liat Mintz | A ghrelin splice variant for use in the prevention or treatment of high cholesterol levels |
| MX2009012969A (es) | 2007-05-31 | 2010-04-27 | Alize Pharma Sas | Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos. |
| EP2067481A1 (en) | 2007-12-03 | 2009-06-10 | Charité-Universitätsmedizin Berlin | Therapeutic use of desacyl ghrelin |
-
2009
- 2009-06-11 US US12/482,882 patent/US8476408B2/en not_active Expired - Fee Related
- 2009-06-12 US US12/996,244 patent/US20110160121A1/en not_active Abandoned
- 2009-06-12 WO PCT/EP2009/057263 patent/WO2009150214A2/en not_active Ceased
- 2009-06-12 MX MX2010013677A patent/MX2010013677A/es active IP Right Grant
- 2009-06-12 AU AU2009256558A patent/AU2009256558B2/en not_active Ceased
- 2009-06-12 CA CA2723270A patent/CA2723270C/en not_active Expired - Fee Related
- 2009-06-12 JP JP2011512988A patent/JP5481473B2/ja not_active Expired - Fee Related
- 2009-06-12 EP EP09761776A patent/EP2310041B1/en active Active
- 2009-06-12 CN CN2009801222849A patent/CN102065883A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011522864A5 (cg-RX-API-DMAC7.html) | ||
| JP2010031018A5 (cg-RX-API-DMAC7.html) | ||
| JP2014501762A5 (cg-RX-API-DMAC7.html) | ||
| ME02662B (me) | Niskofrekventna terapija glatiramer acetatom | |
| JP2013515009A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516016A5 (cg-RX-API-DMAC7.html) | ||
| JP2018052983A5 (cg-RX-API-DMAC7.html) | ||
| JP2011225596A5 (cg-RX-API-DMAC7.html) | ||
| JP2010532761A5 (cg-RX-API-DMAC7.html) | ||
| JP2011528333A5 (cg-RX-API-DMAC7.html) | ||
| RU2013139651A (ru) | Новые соединения, влияющие на пищевое поведение | |
| FI3356386T3 (fi) | Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä | |
| JP2013510169A5 (cg-RX-API-DMAC7.html) | ||
| JP2014506579A5 (cg-RX-API-DMAC7.html) | ||
| JP2009519949A5 (cg-RX-API-DMAC7.html) | ||
| JP2017509690A5 (cg-RX-API-DMAC7.html) | ||
| RU2007143510A (ru) | Инсулиновые композиции | |
| WO2009150214A3 (en) | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease | |
| AU2021247258A1 (en) | Anti-CD6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including COVID-19 | |
| WO2007029041A2 (en) | Interferon lambda therapy for treatment of respiratory diseases | |
| US20230210942A1 (en) | Methods and compositions for modulating endothelial cell dysfunction | |
| AU747885B2 (en) | Treatment of disease states | |
| Durante-Mangoni et al. | Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease | |
| WO2010132562A3 (en) | Transdermal delivery of metformin | |
| JP2013506666A5 (ja) | 医薬組成物 |